IRVINE,
Calif., May 23, 2024 /PRNewswire/ --
Postsurgical Therapeutics, Inc. (PST) today announced the
successful completion of an in vivo study of its proprietary
injectable gel formulation containing two drugs used to treat
several types of KRAS mutated solid tumors. The results
demonstrated suppression or elimination of tumors in mice. The
drugs were developed and commercialized by others for oral
administration.
PST's proprietary controlled release gel formulation of the
drugs was administered by intratumoral injection to the target
tumors. The drugs used target the MAPK and PI3K pathways using a
combination of MEK and mTOR inhibitors, which are important for
treatment of several major tumor types. The formulation was
shown to be effective, reducing growth or eradicating tumors in
several KRAS mutations across multiple cancer cell lines, including
pancreatic (Mia PaCa-2, G12C), lung (NCI H441, G12V), colorectal
(SW3, G12V), and gastric (AGS, G12D) cancers.
In clinical practice, multiple drugs are often required as
resistance to a single drug limits its therapeutic use. However,
clinic investigations by others of combinations of these two drugs
by oral administration have not been able to determine a safe and
effective dose due to cumulative toxicity as reported by Tolcher
(Tolcher et al. Annals of Oncology, 58-64 (2015)) and by Nikanjam
(Nikanjam et al. J. Hematol. Oncol. Pharm, 19-25 (2023)).
Soonkap Hahn, Ph.D., Chairman, Chief Scientific Officer, and
Founder of PST stated that "If clinical trials confirm the
results of this study, we believe the resulting product will have
the potential to extend the lives of treated patients. We will also
investigate the potential reduction in toxicity by local
administration."
PST is a development stage company based in Irvine, California. PST uses advanced drug
delivery technologies to formulate products with enhanced efficacy
and safety for the treatment of solid tumors and other therapy
areas.
PST intends to develop and commercialize products based on its
technology through collaborations with corporate partners and
others.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/overcoming-resistance-and-toxicity-hurdles-psts-localized-drug-delivery-technology-may-unlock-combined-mekmtor-inhibition-for-multiple-kras-tumors-types-302153627.html
SOURCE Postsurgical Therapeutics